| 0 (0%) | 09-27 09:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.03  |
1-year : | 1.13 |
| Resists | First : | 0.88 |
Second : | 0.97 |
| Pivot price | 0.85  |
|||
| Supports | First : | 0.74 |
Second : | 0.61 |
| MAs | MA(5) : | 0.8 |
MA(20) : | 0.84 |
| MA(100) : | 0.78 |
MA(250) : | 2.07 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 20.4 |
D(3) : | 19.7 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 6.88 | Low : | 0.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IBIO ] has closed above bottom band by 26.3%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.81 - 0.82 | 0.82 - 0.82 |
| Low: | 0.77 - 0.78 | 0.78 - 0.78 |
| Close: | 0.8 - 0.81 | 0.81 - 0.82 |
Fri, 26 Sep 2025
What analysts say about IBIO stock - Trading Psychology Tips & Unlock Free Weekly Portfolio Checkups - Early Times
Tue, 16 Sep 2025
CFO Felipe Duran leads iBio’s financial strategy with agility and vision - BioXconomy
Fri, 05 Sep 2025
iBio Sets Sights on Clinic for Treatments of Obesity, Heart Disease - San Diego Business Journal
Fri, 05 Sep 2025
Exclusive: Interview with iBio and How it Plans to Use New Capital from its Latest Public Offering - Fred Grier | Substack
Mon, 25 Aug 2025
iBio Announces Closing of $50 Million Public Offering - GlobeNewswire
Mon, 25 Aug 2025
$100M Potential Raise: iBio's Major Public Offering Draws Top Investment Firms for Antibody Pipeline - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.861e+007 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 554 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.783e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 599 % |
| Return on Equity (ttm) | -44.8 % |
| Qtrly Rev. Growth | 400000 % |
| Gross Profit (p.s.) | 16.62 |
| Sales Per Share | -118.05 |
| EBITDA (p.s.) | 465116 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.9 |
| Dividend | 0 |
| Forward Dividend | 2.14e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|